Healthcare Services

Thyroid Cancer Diagnostics Market Insights Exploring Expansion Opportunities Through 2030

June 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Rise In Market Size Of The Thyroid Cancer Diagnostics Market During The Forecast Period?

The thyroid cancer diagnostics market has experienced significant expansion in recent years. It is anticipated to increase from $3.15 billion in 2025 to $3.34 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.0%. The expansion observed historically is attributable to factors such as the rising occurrence of thyroid nodules, enhanced access to ultrasound imaging, advancements in biopsy procedures, the proliferation of cancer diagnostic laboratories, and increasing clinical understanding regarding thyroid cancers.

The thyroid cancer diagnostics market is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach $4.25 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.2%. Factors driving this growth during the forecast period include the expanding use of AI-assisted imaging diagnostics, a heightened need for personalized oncology solutions, the broadening of molecular testing panels, increased funding for early cancer detection, and a stronger emphasis on precision diagnostics. Key developments expected over this period encompass a greater reliance on molecular diagnostic methods, more widespread adoption of imaging-based screening, the increasing incorporation of genetic testing, the enlargement of early detection initiatives, and improvements in diagnostic precision and speed.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12030&type=smp

Which Growth Drivers Are Expected To Support The Thyroid Cancer Diagnostics Market Forward?

The expanding occurrence of thyroid cancer is fueling the expansion of the thyroid cancer diagnostic market moving ahead. Thyroid cancer is an ailment affecting the thyroid gland, which is located near the throat’s base and generates hormones vital for regulating body temperature, heart rate, blood pressure, and weight. Diagnostics for thyroid cancer aid in identifying the disease through early detection, which can lead to enhanced treatment results. Consequently, the rising incidence of thyroid cancer boosts the demand within the diagnostic market. For example, a report from September 2023 by the American Cancer Society, a US-based non-profit organization, estimated around 43,720 new thyroid cancer cases in 2023, comprising 12,540 in men and 31,180 in women. Deaths from thyroid cancer that same year were projected to be approximately 2,120, consisting of 970 men and 1,150 women. Thus, the growing prevalence of thyroid cancer is a key driver for the thyroid cancer diagnostic market.

What Are The Core Segment Classifications In The Thyroid Cancer Diagnostics Market?

The thyroid cancer diagnostics market covered in this report is segmented –

1) By Technique Type: Imaging Test, Blood Test, Biopsy, Other Test Types

2) By Disease Type: Papillary Carcinoma, Follicular Carcinoma, Other Diseases

3) By End-User: Hospital Laboratories, Cancer Diagnostic Centers, Research Institutes, Other End-Users

Subsegments:

1) By Imaging Test: Ultrasound Imaging, Computed Tomography (CT) Scans, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET) Scans, Radioactive Iodine Scans

2) By Blood Test: Thyroid Function Tests, Tumor Marker Tests, Genetic Testing For Thyroid Cancer

3) By Biopsy: Fine Needle Aspiration (FNA) Biopsy, Core Needle Biopsy, Surgical Biopsy

4) By Other Test Type: Molecular Diagnostics, Immunohistochemistry Tests, Histopathological Analysis

Which Trends Are Influencing The Direction Of The Thyroid Cancer Diagnostics Market?

Leading companies operating in the thrombotic thrombocytopenic purpura (TTP) market are concentrating on developing innovative therapies, such as recombinant enzyme replacement therapy, to enhance treatment effectiveness and patient outcomes. Recombinant enzyme replacement therapy involves a medical procedure where synthetic or bioengineered enzymes are administered to patients with enzyme deficiency disorders to restore normal metabolic function. For example, in November 2023, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical firm, announced ADZYNMA, a recombinant ADAMTS13 enzyme replacement therapy that received approval from the U.S. Food and Drug Administration (FDA), a US-based government agency. This product is the first and only treatment for congenital thrombotic thrombocytopenic purpura (cTTP) in both adult and pediatric patients. Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra-rare blood clotting disorder caused by an ADAMTS13 enzyme deficiency. Clinical trials supporting this approval demonstrated that ADZYNMA effectively reduced the risk of acute TTP events, and it is now available in the U.S. for both prophylactic and on-demand treatment.

Which Organizations Are Involved In The Thyroid Cancer Diagnostics Market?

Major companies operating in the thyroid cancer diagnostics market are General Electric, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Toshiba Corporation, Siemens Healthcare GmbH, FUJIFILM Holdings Corporation, Koninklijke Philips N.V., Agilent Technologies Inc., Hologic Inc., Illumina Inc., BioMérieux SA, Bio-Rad Laboratories Inc., Quest Diagnostics Inc., Qiagen N.V., Cepheid, Veracyte Inc., DiaSorin S.p.A., Myriad Genetics Inc., Interpace Biosciences, Guardant Health, BillionToOne, Canon Inc., Beckman Coulter Inc.

Access The Complete Thyroid Cancer Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-diagnostics-global-market-report

Which Regional Market Leads The Thyroid Cancer Diagnostics Market?

North America was the largest region in the thyroid cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the thyroid cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Thyroid Cancer Diagnostics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12030&type=smp

Browse Through More Reports Similar to the Global Thyroid Cancer Diagnostics Market 2026, By The Business Research Company

Thyroid Function Test Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/thyroid-function-test-global-market-report

Cancer Diagnostics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Thyroid Cancer Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795